Information Provided By:
Fly News Breaks for January 30, 2017
RGLS
Jan 30, 2017 | 08:38 EDT
As previously reported, Needham analyst Alan Carr downgraded Regulus to Hold from Buy due to absence of near-term material clinical milestones. The analyst believes opportunity for the company to capture value in HCV is fading given growing number of effective once-daily oral options.
News For RGLS From the Last 2 Days
There are no results for your query RGLS